MX2016008304A - Usos de oligouronatos en el tratamiento de cancer. - Google Patents
Usos de oligouronatos en el tratamiento de cancer.Info
- Publication number
- MX2016008304A MX2016008304A MX2016008304A MX2016008304A MX2016008304A MX 2016008304 A MX2016008304 A MX 2016008304A MX 2016008304 A MX2016008304 A MX 2016008304A MX 2016008304 A MX2016008304 A MX 2016008304A MX 2016008304 A MX2016008304 A MX 2016008304A
- Authority
- MX
- Mexico
- Prior art keywords
- oligouronates
- cancer
- relates
- agent
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Esta invención se refiere al uso de un oligouronato en el tratamiento o prevención de cáncer, tanto como un agente anticancerígeno, que es como un agente eficaz contra el cáncer en sí, y como herramienta de suministro de fármaco, que es para mejorar o promover el suministro de un agente anticancerígeno adicional o diferente, por ejemplo, fármaco de quimioterapia o agente inmunoterapéutico. Por lo tanto, la invención se refiere al uso en la prevención de cáncer o el tratamiento de oligouronatos tanto solos como en combinación con uno o más agentes anticancerígenos adicionales. La invención también se refiere a métodos para tratar o prevenir cáncer utilizando oligouronatos, ya sea solo o en combinación con uno o más agentes anticancerígenos adicionales.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB201322958A GB201322958D0 (en) | 2013-12-23 | 2013-12-23 | Uses of oligouronates in cancer treatment |
GB201410695A GB201410695D0 (en) | 2014-06-16 | 2014-06-16 | Uses of oligouronates in cancer treatment |
PCT/EP2014/079178 WO2015097224A1 (en) | 2013-12-23 | 2014-12-23 | Uses of oligouronates in cancer treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2016008304A true MX2016008304A (es) | 2017-01-09 |
Family
ID=52232205
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016008304A MX2016008304A (es) | 2013-12-23 | 2014-12-23 | Usos de oligouronatos en el tratamiento de cancer. |
Country Status (7)
Country | Link |
---|---|
US (1) | US20160346313A1 (es) |
EP (1) | EP3086847A1 (es) |
JP (1) | JP2017501221A (es) |
AU (1) | AU2014372566B2 (es) |
CA (1) | CA2934950A1 (es) |
MX (1) | MX2016008304A (es) |
WO (1) | WO2015097224A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102016113018A1 (de) * | 2016-07-14 | 2018-01-18 | Abbas Mirshafiey | Pharmazeutische Verwendung von beta-D-Mannuronsäure |
WO2018127819A1 (en) | 2017-01-03 | 2018-07-12 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing alginates as biodegradable antibacterial scaffolds and methods pertaining thereto |
EP3600338A4 (en) | 2017-03-28 | 2020-10-28 | The University of North Carolina at Chapel Hill | NITRIC OXIDE RELEASING POLYAMINOGLYCOSIDES AS BIODEGRADABLE ANTIBACTERIAL SCAFFOLDS AND RELATED PROCESSES |
US10969135B2 (en) | 2017-07-27 | 2021-04-06 | Johnson Controls Technology Company | Central plant control system with computation reduction based on sensitivity analysis |
WO2019173539A1 (en) | 2018-03-06 | 2019-09-12 | The University Of North Carolina At Chapel Hill | Nitric oxide-releasing cyclodextrins as biodegradable antibacterial scaffolds and methods pertaining thereto |
JP2022516461A (ja) | 2018-12-28 | 2022-02-28 | ザ ユニバーシティ オブ ノース カロライナ アット チャペル ヒル | 一酸化窒素放出抗菌性ポリマーおよびそれから製造された足場、ならびにそれに関する方法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP4186294B2 (ja) * | 1999-02-26 | 2008-11-26 | セイコーエプソン株式会社 | ポリグルロン酸の製造方法 |
JP2005145885A (ja) * | 2003-11-14 | 2005-06-09 | Japan Science & Technology Agency | アルギン酸オリゴマーからなる免疫機構賦活剤 |
GB2430881B (en) * | 2005-10-06 | 2010-10-13 | Ntnu Technology Transfer As | Oligoelectrolyte polyols for the treatment of mucosal hyperviscosity |
WO2007069468A1 (ja) * | 2005-12-14 | 2007-06-21 | Nagasaki University | サイトカイン分泌促進剤 |
WO2008140500A2 (en) * | 2006-12-08 | 2008-11-20 | The University Of Miami | Hyaluronidase inhibitors as anti-cancer agents |
GB0707096D0 (en) * | 2007-04-12 | 2007-05-23 | Ntnu Technology Transfer As | Method |
HUE034051T2 (en) * | 2007-11-27 | 2018-01-29 | Algipharma As | Use of alginate-containing oligomers to combat biofilms |
GB0904942D0 (en) * | 2009-03-23 | 2009-05-06 | Ntnu Technology Transfer As | Composition |
GB0909529D0 (en) * | 2009-06-03 | 2009-07-15 | Algipharma Ipr As | Alginate oligomers for the inhibition of microbial adherence to surfaces |
JP2013010700A (ja) * | 2011-06-28 | 2013-01-17 | Meiji Univ | ヒアルロニダーゼ阻害剤 |
-
2014
- 2014-12-23 WO PCT/EP2014/079178 patent/WO2015097224A1/en active Application Filing
- 2014-12-23 JP JP2016560044A patent/JP2017501221A/ja active Pending
- 2014-12-23 AU AU2014372566A patent/AU2014372566B2/en not_active Ceased
- 2014-12-23 US US15/107,424 patent/US20160346313A1/en not_active Abandoned
- 2014-12-23 EP EP14820882.0A patent/EP3086847A1/en not_active Withdrawn
- 2014-12-23 MX MX2016008304A patent/MX2016008304A/es unknown
- 2014-12-23 CA CA2934950A patent/CA2934950A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
JP2017501221A (ja) | 2017-01-12 |
US20160346313A1 (en) | 2016-12-01 |
AU2014372566A1 (en) | 2016-07-07 |
CA2934950A1 (en) | 2015-07-02 |
AU2014372566B2 (en) | 2017-07-20 |
EP3086847A1 (en) | 2016-11-02 |
WO2015097224A1 (en) | 2015-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA39906A (fr) | Polythérapies pour le traitement du cancer | |
PH12017500070A1 (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
MX2016006726A (es) | Composiciones que comprenden anticuerpos anti-molecula de adhesion celular relacionada con antigeno carcinoembrionario 1 y anti-muerte celular programada para la terapia contra el cancer. | |
MD20170073A2 (ro) | Terapii combinate pentru tratarea cancerelor | |
TW201613887A (en) | Antiproliferative compounds and methods of use thereof | |
WO2013177187A3 (en) | Synergistic tumor treatment with extended-pk il-2 and therapeutic agents | |
EA201992251A1 (ru) | Противораковые вакцины и способы лечения с их применением | |
PH12016500511A1 (en) | Selective grp94 inhibitors and uses thereof | |
NZ749218A (en) | Androgen receptor modulator and uses thereof | |
MX2016008304A (es) | Usos de oligouronatos en el tratamiento de cancer. | |
MX2015014046A (es) | Combinaciones de farmacos para tratar cancer. | |
SG11201802915WA (en) | Cancer treatment composition combining anti-cd26 antibody and other anticancer agent | |
MX2019013808A (es) | Compuestos desestabilizadores de microtubulina para usarse en el tratamiento del cancer. | |
MX2017015896A (es) | Agente anticancerigeno. | |
CL2015003595A1 (es) | Inhibidores/antiandrógenos novedosos de cyp17 | |
MX2018005233A (es) | Combinacion de inhibidor de bcl-2 e inhibidor de mek para el tratamiento de cancer. | |
PH12015502342B1 (en) | Combination therapy comprising a dihydropyrazino-pyrazine compound and an androgen receptor antagonist for treating prostate cancer | |
MX2019005349A (es) | Uso de analogos de sangliferina macrociclicos como compuestos anticancerigenos. | |
PH12015502815A1 (en) | Use of sigma receptor ligands for the prevention and treatment of pain associated to interstitial cystitis/bladder pain syndrome (ic/bps) | |
MX2016015568A (es) | Derivados de nucleosidos para el tratamiento del cancer. | |
TN2013000333A1 (en) | Combinations comprising macitentan for the treatment of glioblastoma multiforme | |
WO2019043176A3 (en) | HISTONE-DEACETYLASE INHIBITOR IN COMBINATION WITH ANTIMETABOLITE AGENT FOR CANCER THERAPY | |
PH12016501838A1 (en) | Compounds and their methods of use | |
PH12018500450A1 (en) | Immunity enhancing agent for cancer by allergin-1 antagonist | |
MX2017013666A (es) | Terapia de combinacion de agente anti-fuctactico y agente de inmunoterapia y composiciones para el tratamiento de cancer. |